Document:

exhibit10_12.htm

 

 

Exhibit 10.12

 

 

AMENDMENT TO LICENSE AGREEMENT

 

This Amendment ("Amendment'"). effective as of ________, 2011. modifies the terms of the License Agreement ("Agreement") between BioZone Laboratories. Inc. and BetaZone Laboratories LLC dated November 7. 2006.

 

Whereas:

 

	
A.

	
BioZone Phamlaceutical. Inc .. a Delaware corporation having a principal place of business at 580 Garcia Avenue. Pittsburg. CA 94565 ("BPI") is the successor in interest to BioZone Laboratories. Inc. ("BU") and the assignee of the BLI’s entire interest under the Agreement:

 

	
B.

	
BetaZone Laboratories LLC ("BetaZone") has developed the ophthalmic products listed in the attached schedule ("Existing Ophthalmic Products") pursuant to the Agreement: and

 

	
C.

	
BLI wishes to enter into a new separate license agreement relating to ophthalmic products with a third party;

 

Therefore. BPI and BetaZone agree as follows.

 

	
1.

	
BetaZone shall have the right to continue to market and sell Existing Ophthalmic Products pursuant to the Agreement. Such right shall include all other rights necessary to implement such marketing and sales activity. including the right to continue manufacture of Existing Ophthalmic Products pursuant to the Agreement.

 

	
2.

	
BetaZone shall not develop. market or sell any new therapeutic and/or preventative ophthalmic products incorporating the confidential information and/or Know-How as defined in the Agreement.

 

 

	
Signed:

	  	  
	
/s/ Camillo Rey

	  	
/s/ Brian Keller

	
Managing Director

	  	
CEO

	
BetaZone

	  	
BPI

	  	  	  
	
04/04/2011

	  	  
	
Date

	  	
Dateexhibit10_13.htm

 

 

 

Exhibit 10.13

 

 

 

 

 

SECOND AMENDMENT TO LICENSE AGREEMENT

BETWEEN BIOZONE LABORATORIES, INC

AND BETAZONE LABORATORIES, LLC

 

This Second Amendment (the “Second Amendment”), effective as of June 29, 2011, modifies the terms of the License Agreement (the “License”) between BioZone Laboratories, Inc. (“BioZone Labs”) and BetaZone Laboratories, LLC (‘BetaZone Labs or Licensee”) dated as of November 7, 2006 as modified by the Amendment to the License Agreement between BioZone Pharmaceutical, Inc. (“BPI”) and BetaZone Labs (the “First Amendment”) effective as of April [   ], 2011. All terms used herein shall have the definition applied to such terms in the License and the First Amendment.

 

 

FIRST:                      Exhibit B attached to the License shall be deleted and replaced with Exhibit B-1 attached hereto. The parties hereto acknowledge that BetaZone Labs shall have the continued right to market and sell the Existing Ophthalmic Products listed on the Schedule of Existing Ophthalmic Products attached to the First Amendment.

 

 

SECOND:                      Section1, Grant of License, shall be amended as follows:

 

 

A.           Paragraph 1.2 shall be deleted in its entirety and replaced with the following:

 

 

	
  

	
1.2

	
“For purposes of this Agreement, the “Territory’ shall be defined as Mexico and the countries included in Central America and South America, Asia and Eastern Europe.”

 

 

	
B.

	
New Paragraph 1.4 shall be added, which reads as follows

 

 

	
  

	
1.4

	
“Notwithstanding the foregoing, Licensee shall have the continued right to market and sell QuSome products outside the Territory with the prior written consent of Licensor.”

 

 

THIRD:                      BPI hereby consents to Licensee’s right to market and sell the QuSome products listed on Schedule B-2 attached hereto in the respective countries shown on such schedule (the “Permitted Products”).

 

 

FOURTH:                      BPI acknowledges that BetaZone Labs has licensed the QuSome technology platform to certain sub-licensees for development and sale of any product using the QuSome technology in certain specified territories. BPI hereby consents to the rights granted by BetaZone Labs to Biolab Sanus Farmaceutica, Ltda for the development and sale of Qusome products in Brazil; and to Laboratorios La Sante for the development and sale of Qusome Products in the countries included in Central America and South America, excluding Argentina, Brazil, Chile and Uruguay.

 

 

FIFTH:                      BetaZone Labs shall use its commercially reasonable efforts on a continuous basis to develop, market and sell the QuSome products listed on Schedules B-1 and B-2 attached hereto.   In the event that BetaZone Labs fails to sell or license any particular QuSome product listed on Schedules B-1 and B-2 within 24 months from the date hereof, BPI shall have the right to remove such product from Schedule B-1 or Schedule B-2.

 

 

SIXTH:                      BioZone Labs has developed certain proprietary purified lipids that it refers to as EquaSomes. BetaZone Labs agrees that the License does not apply to products containing EquaSomes except for the Existing Ophthalmic Products and the products listed on Schedule B-3 attached hereto.

 

 

 

  

  

  

 

 

SEVENTH:                                BetaZone Labs agrees to purchase QuSomes and EquaSomes exclusively from BPI or its designee.

 

 

EIGHTH:                      Notwithstanding Paragraph 11 of the License, BetaZone Labs agrees not to transfer its rights, duties and privileges under the License and/or the First or Second Amendment with the prior written consent of BPI.

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to be executed as of the date shown above.

 

BETAZONE LABORATORIES, LLC

By:____________________________

Name: Camilo Rey

Title: Managing Director

BIOZONE PHARMACEUTICALS, INC

By:____________________________

Name:

Title:Exhibit 10.24
  
 SECOND AMENDMENT OF Purchase and Sale CONTRACT
  
 THIS SECOND AMENDMENT OF PURCHASE AND SALE CONTRACT(this “Amendment”) is entered into effective as of the 1st day of July, 2011 (“Effective Date”), by and betweenAPARTMENT LODGE 17A LLC, a Colorado limited liability company, having an address at c/o AIMCO, 4582 South Ulster Street Parkway, Suite 1100, Denver, Colorado 80237 (“Seller”), and FF REALTY LLC, a Delaware limited liability company, having a principal address at 5510 Morehouse Drive, Suite 200, San Diego, California 92121 (“Purchaser”).
 RECITALS
 A.        Seller and Purchaser entered into that certain Purchase and Sale Contract, dated as of May 23, 2011 (as amended by that certain First Amendment to Purchase and Sale Contract dated as if June 3, 2011, collectively, the “Contract”), regarding real property located in the City and County of Denver, Colorado and more particularly described in the Contract.
 B.         Seller and Purchaser desire to amend the Contract subject to the terms and conditions described below.
 C.        All capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed to them in the Contract.
 NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, Seller and Purchaser agree as follows:
 agreements
 1.                  Incorporation of Recitals.  The foregoing recitals are true and correct and are incorporated herein by reference.
 2.                  Feasibility Period.  Purchaser hereby acknowledges and agrees that as of the date of this Amendment the Feasibility Period has expired and Purchaser’s right to terminate the Contract pursuant to Section 3.2 of the Contract has been permanently waived.
 3.                  Loan Approval Period; New Loan Deadline.  By its execution hereof, Purchaser hereby agrees that (i) the Loan Approval Period and the New Loan Deadline have expired, (ii) all rights of Purchaser under the Contract to extend either such date are hereby waived by Purchaser, (iii) Purchaser’s right to terminate the Contract pursuant to Section 4.7 of the Contract (as modified by the First Amendment to the Contract) is hereby waived by Purchaser, (iv) Purchaser has elected to finance the purchase of the Property using the New Loan, and (v) all provisions of the Contract relating to the New Loan, the Loan Commitment and the Loan Assumption and Release are deemed satisfied and/or waived by Purchaser.
 4.                  Closing Date.  Anything contained in the Contract to the contrary notwithstanding, the Closing shall occur on July 22, 2011 and neither party shall have any right to extend such date unless the other party shall agree in writing (which agreement may be withheld in such other party’s sole discretion).
 5.                  No Further Modification.  Except as modified by this Amendment, the Contract remains unmodified.  The terms and provisions of the Contract as amended by this Amendment remain in full force and effect and are hereby ratified and confirmed.
 6.                  Counterparts.  This Amendment may be executed in multiple counterparts, and all such counterparts together shall be construed as one document.
 7.                  Telecopied/Electronic Mail Signatures.  A counterpart of this Amendment signed by one party to this Amendment and telecopied or sent by electronic mail to another party to this Amendment or its counsel (i) shall have the same effect as an original signed counterpart of this Amendment, and (ii) shall be conclusive proof, admissible in judicial proceedings, of such party’s execution of this Amendment.
  [Remainder of page intentionally left blank; signatures to follow]
  
  

 IN WITNESS WHEREOF, Seller and Purchaser have entered into this Second Amendment as of the date first above stated.
  
 SELLER:
  
 APARTMENT LODGE 17A LLC, 
 a Colorado limited liability company
  
 By: FOX PARTNERS, 
 a California general partnership, 
 its manager
  
 By: FOX CAPITAL MANAGEMENT CORPORATION, 
 a California corporation, 
 its managing general partner
  
  
 By:  /s/Trent A. Johnson
 Name:  Trent A. Johnson
 Title:  Vice President
  

 PURCHASER:
  
 FF REALTY LLC,
 a Delaware limited liability company
  
 By:  /s/Jon A. MacDonald
 Name:  Jon A. MacDonald
 Title:  General Counsel

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]